Month: August 2021

CAMBRIDGE, Mass. and NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, today announced the appointment of Mark A. Velleca, M.D., Ph.D. to its Board of Directors. Dr. Velleca brings over 20 years of leadership experience in the biotechnology industry, particularly in the field of oncology, most recently serving as Chief Executive Officer of G1 Therapeutics. “I am delighted to welcome Mark to the Black Diamond Board of Directors,” said Robert A. Ingram, Chairman of the Board of Directors of Black Diamond Therapeutics. “Mark brings substantial experience in a range of leadership roles in the life sciences sector, and his perspective will be integral as Black Diamond executes...

VANCOUVER, British Columbia, Aug. 10, 2021 (GLOBE NEWSWIRE) — Amerigo Resources Ltd. (TSX: ARG; ARREF: OTC) (“Amerigo” or the “Company”) is pleased to announce that Minera Valle Central (“MVC”), the Company’s 100% owned operation located near Rancagua, Chile, will receive the 2021 San Lorenzo award from Chile’s National Mining Society (SONAMI). The San Lorenzo awards were established by SONAMI in 1999 and are presented annually to members of the Chilean mining community that have made an outstanding contribution to the industry, acted as leaders on specific issues or matters or contributed to regional mining development. The San Lorenzo award will be presented by Mr. Diego Hernández, President of SONAMI, in recognition of MVC’s contribution to mining sustainability and its leadership in tailings treatment. “Receiving...

Revenue Triples after Buyback of US Rights for NATESTO® TORONTO, Aug. 10, 2021 (GLOBE NEWSWIRE) — Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP; OTCQB:ASPCF) today reported its financial results for the three and six-month period ended June 30, 2021. Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards (“IFRS”). Second Quarter HighlightsThe second quarter included full US product sales for NATESTO®, following the Company’s buyback of the rights from Aytu BioPharma on April 1, 2021, resulting in a 219% increase in product revenue compared to the second quarter of fiscal 2020 Total NATESTO® prescriptions (“TRx”) grew by 45% in the second quarter of fiscal 2021 compared to the prior-year period Within the urology segment,...

WASHINGTON, Aug. 10, 2021 (GLOBE NEWSWIRE) — FTI Consulting today announced continued investment in its Broker-Dealer Regulatory & Litigation group within the Financial Services practice in the Forensic and Litigation Consulting segment with the appointment of Jason Sabot as a Senior Managing Director and Stephen P. Glascoe as a Managing Director. Mr. Sabot, who will be based in New York, has extensive in-house, government and regulatory experience, having led and defended complex civil and criminal investigations involving federal securities laws. He will advise and assist FTI Consulting’s financial institution clients with internal investigations, civil and criminal investigations, non-financial regulatory reporting, and remediation plans. Mr. Glascoe, who will be based in Washington, D.C., has more than 40 years of experience...

TORONTO, Aug. 10, 2021 (GLOBE NEWSWIRE) — Auxly Cannabis Group Inc. (TSX – XLY) (OTCQX: CBWTF) (“Auxly” or the “Company“), a leading consumer packaged goods company in the cannabis products market, announced today that it will report earnings results for its second quarter 2021 ended June 30, 2021, on Monday August 16, 2021, before the financial markets open. The Company will host a conference call to discuss the results. The teleconference details are listed below: Date: Monday August 16, 2021 Time: 10:00 a.m. EST North American Toll Free: 1-888-664-6383 A replay of the teleconference will be available within 24 hours after the conclusion of the call on the Company’s website. ON BEHALF OF THE BOARD “Hugo Alves” CEO About Auxly Cannabis Group Inc. (TSX: XLY) Auxly is a leading Canadian...

– Reported positive interim results from ongoing Phase 1 trial in healthy adult volunteers with FTX-6058 for sickle cell disease demonstrating proof of mechanism and proof of biology – – Company plans to initiate enrollment in a Phase 1b clinical trial in sickle cell patients in 4Q 2021 – – Cash runway into 1Q 2023 – – Conference call scheduled for 8:00 a.m. ET today – CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business update and reported financial results for the second quarter of 2021. “This quarter was marked by meaningful progress, particularly as we furthered our efforts with our lead candidates for FSHD and sickle cell disease,” said...

Guangzhou, China, Aug. 10, 2021 (GLOBE NEWSWIRE) — August 10th, 2021 The Company ( “SIAF”) has been severely impacted by the effects of COVID-19 “Pandemic 2020 ”, which effects continue to this day as such presently the Company is no longer a fully reporting company and has dropped from quoting on OTCQX to OTC Pink sheet from September 2020 onward due primarily to the Company’s auditors, which are located in Hong Kong, have been unable to do on-site inspections of the Company’s operations in China due to COVID-19 restrictions to complete the audit of 2019 and 2020. So Basically SIAF is delinquent in its Form 10-Ks for fiscal year end 2019 and 2020, Form 10-Qs for periods ended March 31, 2020, June 30, 2020, September 30, 2020, and March 31, 2021. It will need to amend and restate filings going back to December 31, 2019 to be able...

CARLSBAD, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced that the first patients have been enrolled into a pivotal multi-center study of its ZIP® Interspinous Fixation device for patients suffering from back pain due to symptomatic degenerative disc disease. The REFINE Screwless™ ZIP Study is a multi-center, randomized trial evaluating the Aurora Spine ZIP® Direct Decompression. Aurora Spine anticipates up to 10 interventional Spine and Neuro Surgical sites throughout the US and expects to enroll approximately 100 patients. The ZIP® device is an alternative to more invasive traditional spinal surgery. The ZIP device’s...